Effects of intranasal administration of the peptide antagonist of type I vaniloid receptor (TRPV1) in the rodent central nervous system.
Intranasal administration of the polypeptide APHC3, an antagonist of the TRPV1 receptor, had acute anxiolytic and antidepressant effects, as well as an ability to modify the microglial response to proinflammatory stress and cytokine profile of the hippocampus. However, the acute antidepressant effect of the polypeptide was not related to the attenuation of neuroiflammation and probably had a different mechanism. The use of intranasal administration of the APHC3 peptide as a therapeutic approach aimed at decreasing depression symptoms needs additional studies in order to find the mechanism of action of this polypeptide in the central nervous system (CNS).
Institute of Higher Nervous Activity and Neurophysiology, Russian Academy of Sciences, Moscow, Russia. anna.tishkina@phystech.edu.
A O
AO
Tishkina
Institute of Higher Nervous Activity and Neurophysiology, Russian Academy of Sciences, Moscow, Russia.
E K
EK
Mart'yanova
Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia.
Yu A
YA
Logashina
Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia.
Ya A
YA
Andreev
Kazan (Privolzhskii) Federal University, Kazan, Tatrstan, Russia.
S F
SF
Khaibullina
Kazan (Privolzhskii) Federal University, Kazan, Tatrstan, Russia.
E V
EV
Martynova
Kazan (Privolzhskii) Federal University, Kazan, Tatrstan, Russia.
A A
AA
Rizvanov
Institute of Higher Nervous Activity and Neurophysiology, Russian Academy of Sciences, Moscow, Russia.
N V
NV
Gulyaeva
Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia.
E V
EV
Grishin
D000281:Administration, Intranasal; D000700:Analgesics / Q000008:administration & dosage; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D000928:Antidepressive Agents / Q000008:administration & dosage; D003064:Cnidarian Venoms / Q000008:administration & dosage*; D016207:Cytokines / Q000378:metabolism; D003863:Depression / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology*; D004305:Dose-Response Relationship, Drug; D006624:Hippocampus / Q000187:drug effects* / Q000502:physiology*; D036341:Intercellular Signaling Peptides and Proteins; D008297:Male; D010455:Peptides / Q000008:administration & dosage*; D051381:Rats; D017208:Rats, Wistar; D050916:TRPV Cation Channels / Q000037:antagonists & inhibitors* / Q000378:metabolism; D016896:Treatment Outcome
D000700:Analgesics; D000893:Anti-Inflammatory Agents; D000928:Antidepressive Agents; D003064:Cnidarian Venoms; D016207:Cytokines; D036341:Intercellular Signaling Peptides and Proteins; D010455:Peptides; D050916:TRPV Cation Channels; C493922:Trpv1 protein, rat; C577094:analgesic polypeptide HC3, Heteractis crispa